Date: December 21, 2021
Your Name: <u>Juan Du</u>
Manuscript Title: Serine Hydroxymethyltransferase 2 Predicts Unfavorable Outcomes In
Multiple Cancer: A Meta-Analysis
Manuscript number (if known): TCR-21-2485

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) _x_Nor	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_x_None	
	Teom	Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_x_None	
3	Royalties or licenses	_x_None	
4	Consulting fees	_xNone	
5	Payment or honoraria for	_xNone	

	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	_x_None	
7	Support for attending meetings and/or travel	_x_None	
8	Patents planned, issued or pending	_x_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_x_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_x_None	
11	Stock or stock options	_x_None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_x_None	
13	Other financial or non- financial interests	_x_None	

None.	

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>December 21, 2021</u>			
Your Name: Yongkang Huang			
Manuscript Title: Serine Hydroxymethyltransferase 2 Predicts Unfavorable Outcomes In			
Multiple Cancer: A Meta-Analysis			
Manuscript number (if known): TCR-21-2485			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	T	ime frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_x_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_x_None	
3	Royalties or licenses	_x_None	
4	Consulting fees	_xNone	
5	Payment or honoraria for	x None	

			<u> </u>
	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert	_x_None	
	testimony		
7	Support for attending meetings and/or travel	_x_None	
8	Patents planned, issued or	_x_None	
	pending		
9	Participation on a Data	_x_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary	_x_None	
	role in other board,		
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	_x_None	
11	Stock of Stock options	xivoile	
12	Receipt of equipment,	_x_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	_x_None	
	financial interests		

None.			

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>December 21, 2021</u>
Your Name: Suxian Jing
Manuscript Title: Serine Hydroxymethyltransferase 2 Predicts Unfavorable Outcomes In
Multiple Cancer: A Meta-Analysis
Manuscript number (if known): TCR-21-2485

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	7	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_x_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_x_None	
3	Royalties or licenses	_x_None	
4	Consulting fees	_xNone	
5	Payment or honoraria for	_xNone	

	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	_x_None	
7	Support for attending meetings and/or travel	_x_None	
8	Patents planned, issued or pending	_x_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_x_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_x_None	
11	Stock or stock options	_x_None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_x_None	
13	Other financial or non- financial interests	_x_None	

None.	

Please place an "X" next to the following statement to indicate your agreement:

Date: December 21, 2021				
Your Name: Yongjian Pei				
Manuscript Title: Serine Hydroxymethyltransferase 2 Predicts Unfavorable Outcomes				
In Multiple Cancer: A Meta-Analysis				
Manuscript number (if known): TCR-21-2485				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		ime frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	_x_None	
	No time limit for this		
	item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_x_None	
3	Royalties or licenses	x_None	
4	Consulting fees	_xNone	
5	Payment or honoraria for	_xNone	

			·
	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert	_x_None	
	testimony		
7	Support for attending meetings and/or travel	_x_None	
8	Patents planned, issued or	_x_None	
	pending		
9	Participation on a Data	_x_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary	_x_None	
	role in other board,		
	society, committee or advocacy group, paid or		
	unpaid		
11	Stock or stock options	_x_None	
12	Receipt of equipment,	_x_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	_x_None	
	financial interests		

None.			

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>December 21, 2021</u>
Your Name: <u>Yajuan Qian</u>
Manuscript Title: Serine Hydroxymethyltransferase 2 Predicts Unfavorable Outcomes In
Multiple Cancer: A Meta-Analysis
Manuscript number (if known): TCR-21-2485

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		ime frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	_x_None	
	No time limit for this		
	item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_x_None	
3	Royalties or licenses	x_None	
4	Consulting fees	_xNone	
5	Payment or honoraria for	_xNone	

			·
	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert	_x_None	
	testimony		
7	Support for attending meetings and/or travel	_x_None	
8	Patents planned, issued or	_x_None	
	pending		
9	Participation on a Data	_x_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary	_x_None	
	role in other board,		
	society, committee or advocacy group, paid or		
	unpaid		
11	Stock or stock options	_x_None	
12	Receipt of equipment,	_x_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	_x_None	
	financial interests		

None.			

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>December 22, 2021</u>				
Your Name: Yuanyuan Zeng				
Manuscript Title: Serine Hydroxymethyltransferase 2 Predicts Unfavorable Outcomes In				
Multiple Cancer: A Meta-Analysis				
Manuscript number (if known): TCR-21-2485				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Т	'ime frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China_None (No. 81802885)	The support from the National Natural Science Foundation of China had no effect on results of the manuscript
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_x_None	
3	Royalties or licenses	_x_None	
4	Consulting fees	_xNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_xNone	
6	Payment for expert testimony	_x_None	
7	Support for attending meetings and/or travel	_x_None	
8	Patents planned, issued or pending	x_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_x_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_x_None	
11	Stock or stock options	_x_None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	x_None	
13	Other financial or non- financial interests	_x_None	

This work was supported by the National Natural Science Foundation of China (No. 81802885), which had no effect on results of the manuscript.

Please place an "X" next to the following statement to indicate your agreement: